Mineralys Therapeutics, Inc. Common Stock (MLYS) - Total Assets
Based on the latest financial reports, Mineralys Therapeutics, Inc. Common Stock (MLYS) holds total assets worth $667.85 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Mineralys Therapeutics, Inc. Common Stock - Total Assets Trend (2020–2025)
This chart illustrates how Mineralys Therapeutics, Inc. Common Stock's total assets have evolved over time, based on quarterly financial data. Also see market cap of Mineralys Therapeutics, Inc. Common Stoc for the company's overall valuation and market capitalisation.
Mineralys Therapeutics, Inc. Common Stock - Asset Composition Analysis
Current Asset Composition (December 2025)
Mineralys Therapeutics, Inc. Common Stock's total assets of $667.85 Million consist of 99.9% current assets and 0.1% non-current assets. Review Mineralys Therapeutics, Inc. Common Stoc total liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 26.1% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2020–2025)
This chart illustrates how Mineralys Therapeutics, Inc. Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See MLYS share price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Mineralys Therapeutics, Inc. Common Stock's current assets represent 99.9% of total assets in 2025, an increase from 98.7% in 2020.
- Cash Position: Cash and equivalents constituted 26.1% of total assets in 2025, down from 94.8% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2020.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Mineralys Therapeutics, Inc. Common Stock Competitors by Total Assets
Key competitors of Mineralys Therapeutics, Inc. Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.98 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
USA | $792.26 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.23 Billion |
Mineralys Therapeutics, Inc. Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 34.46 | 15.12 | 2.20 |
| Quick Ratio | 34.46 | 15.12 | 2.20 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $646.48 Million | $313.10 Million | $6.07 Million |
Mineralys Therapeutics, Inc. Common Stock - Advanced Valuation Insights
This section examines the relationship between Mineralys Therapeutics, Inc. Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.78 |
| Latest Market Cap to Assets Ratio | 3.61 |
| Asset Growth Rate (YoY) | 221.4% |
| Total Assets | $661.81 Million |
| Market Capitalization | $2.39 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Mineralys Therapeutics, Inc. Common Stock's assets at a significant premium (3.61x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Mineralys Therapeutics, Inc. Common Stock's assets grew by 221.4% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Mineralys Therapeutics, Inc. Common Stock (2020–2025)
The table below shows the annual total assets of Mineralys Therapeutics, Inc. Common Stock from 2020 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $661.81 Million | +221.42% |
| 2024-12-31 | $205.90 Million | -18.17% |
| 2023-12-31 | $251.64 Million | +119.88% |
| 2022-12-31 | $114.44 Million | +928.69% |
| 2021-12-31 | $11.12 Million | +648.65% |
| 2020-12-31 | $1.49 Million | -- |
About Mineralys Therapeutics, Inc. Common Stock
Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, an… Read more